Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025

Vera Therapeutics, Inc.

2024-FY EPS reported -$2.75

Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.
Cash and equivalents $640.9M as of Dec 31, 2024; sufficient through potential 2026 commercial launch.
Phase 3 ORIGIN trial primary endpoint expected Q2 2025; BLA submission for atacicept planned H2 2025.
Expanded pipeline: atacicept in PMN, FSGS, MCD; acquired next-gen fusion protein VT-109 in 2024.
FDA Breakthrough Therapy Designation granted for atacicept in IgAN during 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.